Current state and future directions of EGFR-directed therapy in head and neck cancer

P Tathineni, N Joshi, MJ Jelinek - Current Treatment Options in Oncology, 2023 - Springer
Opinion Statement Epidermal growth factor receptor (EGFR) is commonly overexpressed in
many head and neck squamous cell carcinomas (HNSCC). With the success of EGFR …

[HTML][HTML] Regorafenib enhances antitumor immune efficacy of anti-PD-L1 immunotherapy on oral squamous cell carcinoma

IT Chiang, YH Lee, ZL Tan, FT Hsu, HF Tu - Biomedicine & …, 2022 - Elsevier
Oral squamous cells carcinoma (OSCC) is the most common oral malignancy that majorly
originated from oral cavity. Though the prognostic and predictive value of targeting …

Oral mucositis: Current knowledge and future directions

SS Shetty, M Maruthi, V Dhara, JAA de Arruda… - Disease-a-Month, 2022 - Elsevier
Oral mucositis secondary to head and neck chemoradiation displays a complex molecular
pathogenesis involving epithelial and microvascular injury, release of pro-inflammatory …

[HTML][HTML] Recent findings on the impact of ErbB receptors status on prognosis and therapy of head and neck squamous cell carcinoma

C Palumbo, M Benvenuto, C Focaccetti… - Frontiers in …, 2023 - frontiersin.org
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer type,
has often an aggressive course and is poorly responsive to current therapeutic approaches …

[HTML][HTML] T cell effects and mechanisms in immunotherapy of head and neck tumors

Y Xiang, M Gong, Y Deng, H Wang, D Ye - Cell Communication and …, 2023 - Springer
Head and neck tumors (HNCs) are a common tumor in otorhinolaryngology head and neck
surgery, accounting for 5% of all malignant tumors in the body and are the sixth most …

[HTML][HTML] Immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck

RW Hsieh, S Borson, A Tsagianni… - Frontiers in oncology, 2021 - frontiersin.org
Head and neck cancer is the 6th most common cancer worldwide with the most common
histology being squamous cell carcinoma (HNSCC). While the majority of patients present at …

[HTML][HTML] Advantages of the combinatorial molecular targeted therapy of head and neck cancer—A step before anakoinosis-based personalized treatment

R Kleszcz - Cancers, 2023 - mdpi.com
Simple Summary Head and Neck Squamous Cell Carcinoma (HNSCC) is a major threat to
public health around the world. Its occurrence is linked to genetic events and environmental …

Pembrolizumab in the first-line treatment of advanced head and neck cancer

LG de Sousa, R Ferrarotto - Expert review of anticancer therapy, 2021 - Taylor & Francis
Introduction Recurrent or metastatic (R/M) head and neck squamous cell carcinoma
(HNSCC) is associated with dismal prognosis and has limited therapeutic options. PD-1/PD …

Genome-wide open reading frame profiling identifies fibroblast growth factor signaling as a driver of PD-L1 expression in head and neck squamous cell carcinoma

JE Mann, JD Smith, A Kulkarni, SK Foltin, EB Scheftz… - Oral Oncology, 2023 - Elsevier
Head and neck squamous cell carcinomas (HNSCC) are associated with significant
treatment-related morbidity and poor disease-free and disease-specific survival, especially …

BCA101 is a tumor-targeted bifunctional fusion antibody that simultaneously inhibits EGFR and TGFβ signaling to durably suppress tumor growth

SR Boreddy, R Nair, PK Pandey, A Kuriakose… - Cancer Research, 2023 - AACR
The EGFR and TGFβ signaling pathways are important mediators of tumorigenesis, and
cross-talk between them contributes to cancer progression and drug resistance. Therapies …